Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal antibodies against CD20, such as rituximab, has revolutionized the treatment of these disorders, greatly improving overall s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mössner, Ekkehard, Brünker, Peter, Moser, Samuel, Püntener, Ursula, Schmidt, Carla, Herter, Sylvia, Grau, Roger, Gerdes, Christian, Nopora, Adam, van Puijenbroek, Erwin, Ferrara, Claudia, Sondermann, Peter, Jäger, Christiane, Strein, Pamela, Fertig, Georg, Friess, Thomas, Schüll, Christine, Bauer, Sabine, Dal Porto, Joseph, Del Nagro, Christopher, Dabbagh, Karim, Dyer, Martin J. S., Poppema, Sibrand, Klein, Christian, Umaña, Pablo
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Immunobiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2881503/
https://ncbi.nlm.nih.gov/pubmed/20194898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-225979
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados